keyword
MENU ▼
Read by QxMD icon Read
search

non-alcoholic steatohepatitis AND (treatment or therapy)

keyword
https://www.readbyqxmd.com/read/29159825/modulation-of-the-intestinal-bile-acid-fxr-fgf15-axis-improves-alcoholic-liver-disease-in-mice
#1
Phillipp Hartmann, Katrin Hochrath, Angela Horvath, Peng Chen, Caroline T Seebauer, Cristina Llorente, Lirui Wang, Yazen Alnouti, Derrick E Fouts, Peter Stärkel, Rohit Loomba, Sally Coulter, Christopher Liddle, Ruth T Yu, Lei Ling, Stephen J Rossi, Alex M DePaoli, Michael Downes, Ronald M Evans, David A Brenner, Bernd Schnabl
Alcoholic liver disease is associated with changes in the intestinal microbiota. Functional consequences of alcohol-associated dysbiosis are largely unknown. The aim of this study was to identify a mechanism of how changes in the intestinal microbiota contribute to alcoholic liver disease. Metagenomic sequencing of intestinal contents demonstrated that chronic ethanol feeding in mice is associated with an overrepresentation of bacterial genomic DNA encoding choloylglycine hydrolase, which deconjugates bile acids in the intestine...
November 21, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29158052/baicalin-attenuates-non-alcoholic-steatohepatitis-by-suppressing-key-regulators-of-lipid-metabolism-inflammation-and-fibrosis-in-mice
#2
Junli Zhang, Haiming Zhang, Xiaoling Deng, Ning Zhang, Beibei Liu, Shengliang Xin, Guixin Li, Keshu Xu
AIMS: Baicalin (BA), an active flavonoid compound originating from the herb of Scutellaria baicalensis Georgi, has been previously shown to exert anti-inflammation and anti-oxidant effects in liver diseases. However, the potential role of BA in the regulation of non-alcoholic steatohepatitis (NASH) remains elusive. In this study, we newly explored the hepatoprotective effects of BA in MCD diet-induced NASH by ameliorating hepatic steatosis, inflammation, fibrosis and apoptosis. MAIN METHODS: NASH was induced in mice fed a methionine and choline-deficient (MCD) diet for 4weeks...
November 17, 2017: Life Sciences
https://www.readbyqxmd.com/read/29151501/the-efficacy-of-corticosteroid-therapy-in-a-patient-with-nonalcoholic-steatohepatitis-overlapping-autoimmune-hepatitis-a-case-report
#3
Takuya Komura, Hajime Ohta, Takuya Seike, Yoshiaki Shimizu, Ryotaro Nakai, Hitoshi Omura, Takashi Kagaya, Satomi Kasashima, Atsuhiro Kawashima, Sakae Oba, Kennichi Harada, Shuichi Kaneko, Masashi Unoura
The overlap of multiple liver diseases can cause the disease activity and severity to worsen rapidly in some cases. We rarely see patients with non-alcoholic steatohepatitis (NASH) with overlapping autoimmune hepatitis (AIH). A 64-year-old woman who had been prescribed oral drugs to treat diabetes and hypertension (metformin 500 mg/day and voglibose 0.9 mg/day, and termisartan 40 mg/day and amlodipine 5 mg/day, respectively) was diagnosed with NASH with histological confirmation. At 68 years of age, her liver injury worsened with an IgG of 2,871 mg/dL and a high serum anti-nuclear antibody (ANA) level of 2,560...
November 20, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29151428/continuous-positive-airway-pressure-in-patients-with-obstructive-sleep-apnea-and-non-alcoholic-steatohepatitis-a-systematic-review-and-meta-analysis
#4
Gonzalo Labarca, Rodrigo Cruz, Jorge Jorquera
STUDY OBJECTIVES: Several studies have reported an association between obstructive sleep apnea (OSA) and several extra-pulmonary issues, such as arterial hypertension and insulin resistance. In recent years, the associations between OSA, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis (NASH) have been published; however, there is a gap between experimental and clinical studies regarding the efficacy of continuous positive airway pressure (CPAP) treatment in patient populations with these conditions...
November 15, 2017: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/29148806/discovery-of-tropifexor-ljn452-a-highly-potent-non-bile-acid-fxr-agonist-for-the-treatment-of-cholestatic-liver-diseases-and-nonalcoholic-steatohepatitis-nash
#5
David C Tully, Paul V Rucker, Donatella Chianelli, Jennifer Williams, Agnes Vidal, Phil B Alper, Daniel Mutnick, Badry Bursulaya, James Schmeits, Xiangdong Wu, Dingjiu Bao, Jocelyn Zoll, Young Kim, Todd Groessl, Peter McNamara, H Martin Seidel, Valentina Molteni, Bo Liu, Andrew Phimister, Sean B Joseph, Bryan Laffitte
The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases bile acid conjugation, transport, and excretion, thereby protecting the liver from the harmful effects of bile accumulation, leading to considerable interest in FXR as a therapeutic target for the treatment of cholestasis and non-alcoholic steatohepatitis. We identified a novel series of highly potent non-bile acid FXR agonists that introduce a bicyclic nortropine-substituted benzothiazole carboxylic acid moiety onto a trisubstituted isoxazole scaffold...
November 16, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29148175/treatment-efficacy-of-a-probiotic-preparation-for-non-alcoholic-steatohepatitis-a-pilot-trial
#6
Elina Manzhalii, Oleksandr Virchenko, Tetyana Falalyeyeva, Tetyana Beregova, Wolfgang Stremmel
AIM: To evaluate the therapeutic effect of a probiotic cocktail containing lactobacilli, bifidobacteria, and Streptococcus thermophilus on non-alcoholic steatohepatitis (NASH). METHODS: In this open-label trial, 75 patients with NASH fed a low-fat/low-calorie diet were randomly divided into the control group (n = 37) and the experimental group (n = 38) also receiving the probiotic cocktail once daily for 12 weeks. RESULTS: All patients were diagnosed with fatty liver by ultrasound examination and had elevated levels of gamma-glutamyl transferase (GGT) and alanine aminotransferase (ALT), and slightly increased body mass index (BMI) and cholesterol levels...
November 17, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/29141573/liver-protective-effects-of-extra-virgin-olive-oil-interaction-between-its-chemical-composition-and-the-cell-signaling-pathways-involved-in-protection
#7
Sandra A Soto-Alarcon, Rodrigo Valenzuela, Alfonso Valenzuela, Luis A Videla
BACKGROUND AND OBJECTIVE: The liver is an organ susceptible to a multitude of injuries that causes liver damage, like steatosis, non-alcoholic steatohepatitis, cirrhosis, hepatocellular carcinoma, and ischemia-reperfusion injury. Extra virgin olive oil (EVOO), presents several protective effects on the liver, reducing hepatic steatosis, hepatocyte ballooning, fibrogenesis, preventing lipid peroxidation, among other effects. Due to its high levels of monounsaturated fatty acids, mainly oleic acid and phenolic compounds, such as hydroxytyrosol and oleuropein, EVOO is able to participate in the activation of different signaling pathways in the hepatocytes involved in the prevention of inflammation, oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and insulin resistance, allowing the prevention or resolution of liver damage...
November 14, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/29122967/hepatic-accumulation-of-s-adenosylmethionine-in-hamsters-with-non-alcoholic-fatty-liver-disease-associated-to-metabolic-syndrome-under-selenium-and-vitamin-e-deficiency
#8
Josep M Del Bas, Benjamín Rodríguez, Francesc Puiggròs, Silvia Mariné, Miguel Angel Rodríguez, David Moriña, Lluís Armengol, Antoni Caimari, Lluís Arola
Progression of non-alcoholic fatty liver disease (NAFLD) in the context of metabolic syndrome (MetS) is only partially explored due to the lack of preclinical models. In order to study the alterations in hepatic metabolism that accompany this condition, we developed a model of MetS accompanied by the onset of steatohepatitis (NASH) by challenging golden hamsters with a high fat diet low in vitamin E and selenium (HFD), since combined deficiency results in hepatic necroinflammation in rodents. Metabolomics and transcriptomics integrated analyses of livers revealed an unexpected accumulation of hepatic S-Adenosylmethionine (SAM) when compared with healthy livers likely due to diminished methylation reactions and repression of GNMT...
November 9, 2017: Clinical Science (1979-)
https://www.readbyqxmd.com/read/29122694/pharmacotherapy-for-nash-current-and-emerging
#9
REVIEW
Monica A Konerman, Jacob C Jones, Stephen A Harrison
Non-alcoholic fatty liver disease (NAFLD) has become one of the most prominent forms of chronic liver disease worldwide, reflecting the epidemic of global obesity. Those with the progressive variant of NAFLD, non-alcoholic steatohepatitis (NASH), are at significantly increased risk of multisystem morbidity and mortality. However, there are currently no approved pharmacologic therapies for NASH. Given the disease burden, there is an important unmet need for pharmacologic treatment options for this patient population...
November 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29121925/advances-and-challenges-in-cirrhosis-and-portal-hypertension
#10
Annalisa Berzigotti
BACKGROUND: Liver cirrhosis is the fourth cause of death in adults in Western countries, with complications of portal hypertension being responsible for most casualties. In order to reduce mortality, development of accurate diagnostic methods for early diagnosis, effective etiologic treatment, improved pharmacological therapy for portal hypertension, and effective therapies for end-stage liver failure are required. DISCUSSION: Early detection of cirrhosis and portal hypertension is now possible using simple non-invasive methods, leading to the advancement of individualized risk stratification in clinical practice...
November 10, 2017: BMC Medicine
https://www.readbyqxmd.com/read/29118561/pilot-study-of-the-prevalence-of-binge-eating-disorder-in-non-alcoholic-fatty-liver-disease-patients
#11
Jinyu Zhang, Omair Abbasi, Lev Malevanchik, Neena Mohan, Richard Denicola, Nicholas Tarangelo, Dina Halegoua-De Marzio
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States. Binge eating disorder (BED) is the most common form of eating disorder. NAFLD and BED have similar risk factors, including obesity, insulin resistance, and metabolic syndrome. The aim of our study was to examine prevalence of BED in NAFLD patients. Methods: We administered the Binge Eating Scale (BES), a questionnaire validated to screen for BED, to NAFLD patients at our Fatty Liver Center...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29108122/pyroptosis-by-caspase11-4-gasdermin-d-pathway-in-alcoholic-hepatitis
#12
Elena Khanova, Raymond Wu, Wen Wang, Rui Yan, Yibu Chen, Samuel W French, Cristina Llorente, Stephanie Q Pan, Qihong Yang, Yuchang Li, Raul Lazaro, Charles Ansong, Richard D Smith, Ramon Bataller, Timothy Morgan, Bernd Schnabl, Hidekazu Tsukamoto
Alcoholic hepatitis (AH) continues to be a disease with high mortality and no efficacious medical treatment. Although severe AH is presented as acute on chronic liver failure, what underlies this transition from chronic alcoholic steatohepatitis (ASH) to AH, is largely unknown. To address this question, unbiased RNA-seq and proteomic analyses were performed on livers of the recently developed AH mouse model which exhibits the shift to AH from chronic ASH upon weekly alcohol binge, and these results are compared with gene expression profiling data from AH patients...
November 6, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29098111/bile-acid-receptors-link-nutrient-sensing-to-metabolic-regulation
#13
Jibiao Li, Tiangang Li
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease in Western populations. Non-alcoholic steatohepatitis (NASH) is a more debilitating form of NAFLD characterized by hepatocellular injury and inflammation, which significantly increase the risk of end-stage liver and cardiovascular diseases. Unfortunately, there are no available drug therapies for NASH. Bile acids are physiological detergent molecules that are synthesized from cholesterol exclusively in the hepatocytes. Bile acids circulate between the liver and intestine, where they are required for cholesterol solubilization in the bile and dietary fat emulsification in the gut...
June 2017: Liver Res
https://www.readbyqxmd.com/read/29095942/serum-high-mobility-group-box-1-protein-levels-are-not-associated-with-either-histological-severity-or-treatment-response-in-children-and-adults-with-nonalcoholic-fatty-liver-disease
#14
Katherine P Yates, Ross Deppe, Megan Comerford, Howard Masuoka, Oscar W Cummings, James Tonascia, Naga Chalasani, Raj Vuppalanchi
AIM: Serum high mobility group box 1 protein (HMGB1) is a proinflammatory molecule that could potentially serve as a biomarker for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) due to its correlation with degree of liver fibrosis. The aim of the current study was to examine the cross-sectional and longitudinal relationships between serum HMGB1 levels and liver histology in adults and children with NAFLD participating in two large randomized controlled trials...
2017: PloS One
https://www.readbyqxmd.com/read/29083037/review-article-the-gut-microbiome-as-a-therapeutic-target-in-the-pathogenesis-and-treatment-of-chronic-liver-disease
#15
REVIEW
C A Woodhouse, V C Patel, A Singanayagam, D L Shawcross
BACKGROUND: Mortality from chronic liver disease is rising exponentially. The liver is intimately linked to the gut via the portal vein, and exposure to gut microbiota and their metabolites translocating across the gut lumen may impact upon both the healthy and diseased liver. Modulation of gut microbiota could prove to be a potential therapeutic target. AIM: To characterise the changes in the gut microbiome that occur in chronic liver disease and to assess the impact of manipulation of the microbiome on the liver...
October 30, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29077272/inhibition-of-md2-dependent-inflammation-attenuates-the-progression-of-non-alcoholic-fatty-liver-disease
#16
Yali Zhang, Beibei Wu, Hailing Zhang, Xiangting Ge, Shilong Ying, Mengwei Hu, Weixin Li, Yi Huang, Li Wang, Chao Chen, Xiaoou Shan, Guang Liang
Non-alcoholic fatty liver disease (NAFLD) can progress to the more serious non-alcoholic steatohepatitis (NASH), characterized by inflammatory injury and fibrosis. The pathogenic basis of NAFLD progressing to NASH is currently unknown, but growing evidence suggests MD2 (myeloid differentiation factor 2), an accessory protein of TLR4, is an important signalling component contributing to this disease. We evaluated the effectiveness of the specific MD2 inhibitor, L6H21, in reducing inflammatory liver injury in a relevant high-fat diet (HFD) mouse model of NASH and in the palmitic acid (PA)-stimulated human liver cell line (HepG2)...
October 27, 2017: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/29075339/berberine-ameliorates-non-alcoholic-steatohepatitis-in-apoe-mice
#17
Jin Yang, Xiao-Jie Ma, Ling Li, Lei Wang, Ying-Gi Chen, Jing Liu, Yan Luo, Zhen-Jie Zhuang, Wen-Jun Yang, Shu-Fei Zang, Jun-Ping Shi
The aim of the present study was to explore the protective effects of Berberine (BBR) against non-alcoholic steatohepatitis (NASH). Male 4-week-old C57BL/6J Apolipoprotein E-deficient (ApoE(-/-)) mice were divided into the following three groups, which were given different diets: Normal chow diet (SC group); high-fat high-cholesterol diet (HFHC group); and HFHC diet supplemented with BBR (BBR group). Serum biochemical indicators of hepatic function and histological liver tissue changes were evaluated. The expression of neutrophil elastase (NE) and genes involved in the inflammatory response was measured...
November 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29067150/care-standards-for-non-alcoholic-fatty-liver-disease-in-the-united-kingdom-2016-a-cross-sectional-survey
#18
David A Sheridan, Guru Aithal, William Alazawi, Michael Allison, Quentin Anstee, Jeremy Cobbold, Shahid Khan, Andrew Fowell, Stuart McPherson, Philip N Newsome, Jude Oben, Jeremy Tomlinson, Emmanouil Tsochatzis
OBJECTIVE: Guidelines for the assessment of non-alcoholic fatty liver disease (NAFLD) have been published in 2016 by National Institute for Health and Care Excellence and European Associations for the study of the Liver-European Association for the study of Diabetes-European Association for the study of Obesity. Prior to publication of these guidelines, we performed a cross-sectional survey of gastroenterologists and hepatologists regarding NAFLD diagnosis and management. DESIGN: An online survey was circulated to members of British Association for the Study of the Liver and British Society of Gastroenterology between February 2016 and May 2016...
October 2017: Frontline Gastroenterology
https://www.readbyqxmd.com/read/29067086/the-effect-of-omega-3-unsaturated-fatty-acids-on-non-alcoholic-fatty-liver-disease-a-systematic-review-and-meta-analysis-of-rcts
#19
REVIEW
Le Yu, Man Yuan, Linchun Wang
OBJECTIVE: During the treatment of diseases such as angiocardiopathy, blood lipid abnormalities and metabolic syndrome, omega-3 unsaturated fatty acids (PUFA) can reduce plasma lipids and improve cardiovascular status, thus ameliorating disease severity. We aimed to explore the effects of PUFA supplementation in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: A systematic literature search was performed during March 2016 for randomized controlled trials using PUFA or fish oil supplementation in patients with NAFLD or non-alcoholic steatohepatitis (NASH)...
July 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29063072/potential-role-of-thymosin-beta-4-in-the-treatment-of-nonalcoholic-fatty-liver-disease
#20
REVIEW
Yong Jiang, Tao Han, Zhi-Guang Zhang, Man Li, Feng-Xiang Qi, Ying Zhang, Ying-Lan Ji
As a result of increased prevalence of obesity worldwide, non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of chronic liver disease. Although most NAFLD cases remain benign, some progress to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma. Therefore, treatment should be considered for NAFLD patients who are likely to progress to nonalcoholic steatohepatitis (NASH) or fibrosis. Thymosin beta 4 (Tβ4), a G-actin sequestering peptide, regulates actin polymerization in mammalian cells...
September 2017: Chronic Dis Transl Med
keyword
keyword
82832
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"